Altogen Biosystems

07/24/2025

Altogen Biosystems is proud to share that the LNCaP Transfection Reagent was cited in U.S. Patent 7,960,357, titled “PKR Activation via Hybridization Chain Reaction.” This patent describes an innovative technique in which programmable nucleic acid structures formed by hybridization chain reaction (HCR) trigger PKR signaling—a critical component of innate immunity and cellular stress response.

LNCaP prostate carcinoma cells were used in these studies, with Altogen’s reagent delivering HCR components directly into cells with high efficiency and minimal toxicity. This enabled the researchers to observe specific activation of PKR and validate the approach for future applications in immunotherapy and gene regulation.

Altogen’s cell-specific transfection reagents remain central to pioneering work in programmable RNA signaling and synthetic gene circuits.

Learn more:
https://altogen.com/product/lncap-transfection-reagent-prostate-carcinoma/

07/24/2025

Colorectal cancer researchers rely on high-efficiency gene delivery tools for tumor model manipulation—and Altogen Biosystems delivers. In a recent validation study, our HT-29 Transfection Reagent achieved over 80% transfection with GFP plasmid and more than 90% gene knockdown using siRNA in HT-29 colorectal adenocarcinoma cells.

These results were achieved without cytotoxicity and in the presence of serum, demonstrating the reagent’s compatibility with standard culture conditions and complex experimental timelines. HT-29 cells are notoriously resistant to transfection due to their epithelial architecture, but Altogen’s reagent is specifically designed to overcome these barriers.

Access the study:https://altogen.com/HT29_Transfection_Reagent.pdf
Product details: https://altogen.com/product/ht-29-transfection-reagent-colorectal-adenocarcinoma/

07/24/2025

Cancer remains one of the most complex and deadly diseases globally. Recent innovations in biotechnology are helping scientists understand cancer at a molecular level, opening doors for new therapies and diagnostics. A recent doctoral thesis published by the University of Westminster explores how microRNAs, delivered via extracellular vesicles, play a critical role in cancer progression, particularly in liver cancer.

Altogen Biosystems is proud to share that our Liver Cancer Transfection Reagent was cited in this research. The high-efficiency, low-toxicity reagent was used to deliver miRNA constructs into hepatocellular carcinoma cells, enabling functional studies of tumor-suppressive and oncogenic miRNAs. This study provides important insights into how miRNAs influence liver cancer pathogenesis and highlights the therapeutic potential of targeting these molecules.

The publication titled *The Role of Extracellular Vesicles in Cancer Progression and MicroRNA-Based Therapeutics* showcases the evolving intersection of cancer biology and biotechnology. The full thesis is available at:https://westminsterresearch.westminster.ac.uk/download/58925b7c0a6cdb93d43b1b2eee841a4b6b608cabf384a21c65e9fbc965de428b/4552688/Momen-Heravi_Fatemah_thesis.pdf
Learn more about the product cited:https://altogen.com/transfection-resource/sirna-transfection/

07/24/2025

Effective gene delivery is essential for advancing cancer research, yet remains a technical barrier in many cell models. A recent thesis from Bilkent University, “Leveraging the Elastic Deformability of Polydimethylsiloxane for High-Throughput Intracellular Delivery”, employed Altogen Biosystems’ GFP‑Expressing Plasmid DNA (Catalog No. 4060) to demonstrate an innovative approach combining mechanical constriction with plasmid transfection.
Using 0.8 μg/mL of Altogen’s GFP plasmid, researchers demonstrated robust fluorescence in mammalian cell lines—including carcinoma-derived models—after passing through mechanically actuated microchannels and subsequent incubation. Viability assays and flow cytometry confirmed minimal cytotoxicity and high gene expression . This provides compelling evidence that mechanical assistance can significantly enhance delivery efficiency, which is crucial for probing gene function in cancer cells.
Altogen’s GFP plasmid is rigorously validated across human and primary cell types, delivering bright and reliable reporter readouts that support mechanistic assays, drug targeting studies, and gene editing evaluations .
As researchers continue to explore nonviral methods for delivering therapeutic genes, tools like Altogen’s GFP plasmid and complementary transfection platforms offer valuable solutions. Explore our product and transfection resources: https://altogen.com/product/gfp-expressing-plasmid-dna-25-ug/
Read the full thesis:https://yoksis.bilkent.edu.tr/pdf/files/95036.pdf

07/23/2025

Altogen Biosystems is proud to share that our LNCaP Transfection Reagent is cited in U.S. Patent 8,497,364, titled “Triggered RNAi.” This patent describes a modular RNAi technology in which gene silencing is triggered only when a specific molecular condition is met, offering greater selectivity and therapeutic potential.

Altogen’s reagent was used to transfect LNCaP prostate cancer cells with engineered RNA constructs that self-assemble into active siRNA only in the presence of a specific trigger. The successful demonstration of this mechanism depended on efficient and non-toxic delivery—capabilities provided by Altogen’s optimized formulation.

This milestone showcases how Altogen’s delivery platforms continue to support innovation in RNA therapeutics, synthetic gene circuits, and cell-type–targeted therapy development.

Learn more about the product:
https://altogen.com/product/lncap-transfection-reagent-prostate-carcinoma/

07/23/2025

Altogen Biosystems is proud to support breakthrough gene therapy research through its nanoparticle-based delivery platform. A recent study, “Protective Effects of miR-30a on Pulmonary Fibrosis via Regulation of TET1” (https://pmc.ncbi.nlm.nih.gov/articles/PMC6247476/pdf/OMCL2018-6053727.pdf), used the Altogen Nanoparticle In Vivo Transfection Reagent to deliver miR-30a mimics intranasally in mice.

The reagent enabled safe and efficient gene silencing of TET1 in lung tissue, significantly reducing fibrosis and improving histological outcomes. This study highlights the potential of miRNA therapeutics and the critical role of advanced delivery systems in pulmonary disease models.

Learn more about the reagent used in this study:
https://altogen.com/product/nanoparticle-in-vivo-transfection-reagent/

07/23/2025

Understanding how cancer cells modify their metabolism is key to developing breakthrough therapies. A recent UC thesis titled “MFGE8 Links Fat Absorption to Triglyceride Hydrolysis via HNF4γ‐Mediated CES1D Activation” employed Altogen Biosystems’ Caco‑2 Cell Transfection Kit to investigate lipid metabolism in human colon carcinoma cells.
Using this kit, researchers achieved over 94% transfection efficiency in Caco‑2 cells to deliver siRNA and plasmid constructs targeting transcription factors and lipid hydrolases such as HNF4γ and CES1D . This allowed for the precise modulation of gene expression, revealing that MFGE8-mediated pathways regulate triglyceride breakdown—a process that may influence tumor growth and chemotherapeutic uptake in colorectal cancer.
Derived from colon adenocarcinoma, Caco‑2 cells are widely used for modeling cancer cell behavior, drug absorption, and metabolic regulation . Altogen’s kit addresses the challenge of transfecting this robust but hard-to-transfect line, making it ideally suited for functional oncology applications.
To learn more about Altogen’s high-efficiency Caco‑2 Cell Transfection Kit and download detailed protocols, visit: https://altogen.com/product/caco-2-transfection-reagent-colon-carcinoma-cells/
Read the full thesis here:https://escholarship.org/content/qt2dw384dm/qt2dw384dm_noSplash_66dc8bebe925aa8cce77219940814535.pdf

07/22/2025

Altogen Biosystems is proud to announce that the Lipid In Vivo Transfection Reagent has been cited in U.S. Patent 8,614,305, titled “Nonviral Gene Delivery Vector Iopamidol, Protamine, Ethiodized Oil Reagent (VIPER).”

The patent describes VIPER, a multifunctional delivery vector that uses radiographic agents and protamine-based condensation to transport nucleic acids systemically. Altogen’s lipid reagent was used to benchmark the in vivo transfection performance of the VIPER system, highlighting the reagent’s reliability and tissue-penetrating delivery efficiency.

Altogen’s reagent was critical in validating that the new VIPER formulation can achieve comparable or improved gene expression while offering imaging-guided delivery advantages.

Learn more about the product featured in this patent:

Lipid-based in vivo transfection reagent designed for efficient delivery to the liver, pancreas, kidney, and various tumor types.

07/22/2025

Altogen Biosystems is excited to share results from a recent study validating its Calu-6 Transfection Reagent in human lung carcinoma cells. Calu-6, an NSCLC-derived cell line, is a critical model in pulmonary oncology but poses moderate challenges to standard transfection methods.

In this study (https://altogen.com/Calu6_Transfection_Reagent.pdf), the reagent achieved more than 85% plasmid transfection efficiency and over 90% siRNA gene silencing—all under serum-containing conditions and without inducing cytotoxicity.

Altogen’s lipid-based reagent supports gene expression, RNA interference, and therapeutic screening studies in hard-to-transfect lung cancer models.

Learn more about the product here:
https://altogen.com/product/calu-6-transfection-reagent-lung-carcinoma-cell-htb56/

07/22/2025

Checkpoint inhibition via PD‑L1 is at the heart of many cancer immunotherapies, yet delivering targeted gene modulators remains a technical barrier. A recent dissertation from Technical University of Munich, “RNAi‑mediated suppression of PD‑L1…” (Bunse et al., 2020), demonstrates how liver-targeted siRNA delivery can restore immune activity and augment vaccine responses in chronic HBV models—directly relevant to hepatocellular carcinoma therapy.
Altogen Biosystems is honored to have our Liver In Vivo Transfection Kit cited as the enabling tool for hepatic siPD‑L1 delivery. The dissertation revealed that siRNA-based checkpoint inhibition delivered via our kit enhanced antigen clearance, elevated CD8+ T-cell responses, and reduced viral load—surpassing the efficacy of antibody-mediated approaches .
Our kit is specifically formulated for liver targeting, enabling robust lipoplex-mediated delivery of small RNAs with high efficiency and minimal off-target effects. This platform is ideal for preclinical models of liver cancer and metastatic disease where organ-specific delivery is crucial.
To learn how Altogen’s in vivo transfection solutions can drive your research forward, visit our product page: https://altogen.com/product/liver-in-vivo-transfection-kit/
Read the full dissertation to understand the science behind the innovation:https://mediatum.ub.tum.de/doc/1575992/1575992.pdf

Liver-targeted biodegradable reagent for efficient delivery to liver tissue and liver tumors. Effectively delivers cargo molecules with minimal toxicity

07/21/2025

Altogen Biosystems is excited to announce that its LNCaP Transfection Reagent has been cited in U.S. Patent 8,962,582, titled “PKR Activation via Hybridization Chain Reaction.” This patent outlines a novel synthetic biology platform for activating immune signaling pathways using programmable nucleic acid structures.

In the study, prostate cancer cells were transfected with RNA sequences designed to undergo a hybridization chain reaction—self-assembling into long double-stranded RNAs that activate PKR and trigger cellular stress responses. Altogen’s reagent enabled efficient RNA delivery into LNCaP cells, allowing this complex process to unfold with high fidelity and minimal cytotoxicity.

This citation demonstrates the critical role of transfection technology in advancing RNA-based tools for therapeutic and diagnostic innovation.

Learn more:
https://altogen.com/product/lncap-transfection-reagent-prostate-carcinoma/